TAK-285 CAS NO.871026-44-7

We provide customized and high-quality TAK-285 product for your project.

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300?mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300?mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation.